# Sana Biotechnology to Present at June 2026 Investor Conferences
Canonical URL: https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences
Ticker: SANA
Company: Sana Biotechnology
Source: Sana Biotechnology
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.sana.com
## Summary

SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June.

## Article Body
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June.
## Recent Company News
- 2026-07-01 13:00 EST — [Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-association--26e086a1) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology to Present at June 2026 Investor Conferences](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs](https://biopharmsignal.com/news/SANA/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps) — Source: Sana Biotechnology
- 2026-06-25 13:46 EST — [Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Sana Biotechnology
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)